

# MAKING THE RIGHT DRUGS AVAILABLE FOR CHILDREN WITH HIV

5-9 December 2016, Geneva, Switzerland



There are over 1.8 million children living with HIV, but only half of them are receiving the treatment they need. The World Health Organization (WHO) and partners are organizing a series of events in Geneva during the *Paediatrics Week on drug optimization*, from 5-9 December. The events aim to respond to the four key pillars of paediatric treatment optimization:

1. Optimizing HIV treatment options and identifying priority products for children
2. Developing priority paediatric products
3. Optimizing selection and procurement of existing paediatric products
4. Enabling effective introduction, procurement and supply of paediatric products.

## FAST TRACKING THE DEVELOPMENT AND INTRODUCTION OF PAEDIATRIC FORMULATIONS

Meeting of the Global Paediatric Antiretroviral Commitment-to-Action (CTA), 5 December

The Paediatric HIV Commitment-to-Action is identifying innovative approaches to fast-track development of priority paediatric formulations. A new financing mechanism in support of a collaboration framework is being considered with the goal of overcoming existing challenges to the timely development of drugs and formulations for infants and children. This framework focuses on: accelerating the development of new drugs for children, accelerating the development and market uptake of new child-friendly formulations of existing drugs, and financing the development of new formulations of existing drugs. **Open to members and invitees. Focal point: George Siberry, OGAC**

## IMPROVING GUIDANCE FOR PAEDIATRIC HIV TREATMENTS

Meeting of the Paediatric ARV Drug Optimization group - (PADO 3), 6-7 December

Building upon the progress made after the first and second *Paediatric antiretroviral (ARV) drug optimization meeting*, held in Dakar in 2013 and in Geneva in 2014, WHO is convening a third meeting (PADO3) to further advance optimization in paediatric ART. Participants will establish priorities for drug and formulation development and identify research gaps on the use of ARVs for infants, children and adolescents.

**Open to members and invitees. Focal point: Martina Penazzato, WHO**

## DEVELOPING PRIORITY PRODUCTS

Meeting of Paediatric HIV Treatment Initiative (PHTI), 8 December

The *Paediatric HIV Treatment Initiative (PHTI)* aims to accelerate the development and registration of paediatric formulations. Currently, partners are in charge of running several projects in a collaborative manner to optimize the paediatric formulary in line with WHO recommendations. Coordinated by UNITAID, and building upon the expertise and the work of the convening partners — Clinton Health Access Initiative (CHAI), Drugs for Neglected Diseases initiative (DNDi), the Medicines Patent Pool (MPP), UNITAID, and WHO — PHTI aims to create synergies and promote collaboration among various key partners and stakeholders through optimizing development and regulatory pathways for paediatric products. This meeting will review progress and outline key next steps to be undertaken. **Open to PHTI partners and invitees. Focal point: Robert Matiru, UNITAID**

## OPTIMIZING EXISTING PRODUCTS

Interagency Task Team (IATT) formulary revision meeting, 8 December

The *Optimal List of paediatric ARV formulations* jointly published by IATT, WHO and UNICEF provides guidance to funders, implementing partners, procurement agencies and countries to enable a consolidated demand for optimal products and to ensure a sustainable supply of medicines for children living with HIV. The most recent revision was completed in early 2016 to complement the 2016 WHO Consolidated ARV Guidelines. This meeting will focus on implementation guidance for country programs including discussion of strategies to address the phasing-in of newer optimal products and phasing-out of suboptimal options.

**Open to members and invitees. Focal point: Nandita Sugandhi(CHAI)**

## ENABLING EFFECTIVE PROCUREMENT AND SUPPLY

Meeting of the ARV Procurement Working Group, 9 December

The *ARV Procurement Working Group (APWG)* was established to adopt a coordinated approach to the procurement of paediatric ARVs that are challenging to procure as they have low volume demand, including because they are of limited/specialised use or new products or formulations. The group has recently expanded its scope to include adult and adolescent products with the same dynamics. The Global Fund is convening this meeting with partners to share updates as well as to define priorities in innovation and expected outcomes.

**Open to members and invitees. Focal point: Martin Auton, the Global Fund, Wesley Krefl, PFSCM**

## REPORT BACK FROM THE PAEDIATRIC WEEK

ILF/CIPHER webinar, 15 December

To disseminate the main outcomes of the Paediatric Week beyond stakeholders directly involved, the International AIDS Society's (IAS's) Industry Liaison Forum (ILF) and the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) will hold a webinar on Thursday, 15 December 2016, 15:00-16:30 CET. For more information, please contact Sébastien Morin, IAS ([sebastien.morin@iasociety.org](mailto:sebastien.morin@iasociety.org)).

### For information, contact:

World Health Organization - Department of HIV/AIDS  
20, avenue Appia - 1211 Geneva 27 - Switzerland

E-mail: [hiv-aids@who.int](mailto:hiv-aids@who.int)

[www.who.int/hiv](http://www.who.int/hiv)

WHO/HIV/2016.19 © World Health Organization 2016

